Literature DB >> 12602114

Economic burden of illness imposed by severe sepsis in Austria.

Alexandra Schmid1, Heinz Schneider, Astrid Adlof, Karl-Heinz Smolle, Günther Edelmann, Paul Sporn, Michael Frass, Günther Sumann, Wolfgang Koller, Wolfgang Schobersberger.   

Abstract

INTRODUCTION: Sepsis is a life-threatening disease, requiring instant treatment in an intensive care unit (ICU). The aim of this study was to determine the direct and indirect costs occurring in Austria due to this disease. PATIENTS AND METHODS: Direct costs were calculated based on a retrospective chart analysis in four adult Austrian ICUs, evaluating 74 patient records from the years 2000/2001. Patients were identified to have suffered from severe sepsis using ACCP-definitions. Assessed resource use (medication, laboratory analysis, microbiology analysis, consumer-goods, diagnostic procedures, staff costs, and basic bed costs) was linked with related center specific costs to determine direct costs per patient. Indirect costs due to productivity losses were calculated using official statistical material.
RESULTS: The mean length of ICU stay (LOS ICU) of a severely septic patient was 18.1 days. Overall ICU mortality was found to be 43.2% and showed no gender difference. The mean daily direct ICU costs of care for severely septic patients were [symbol: see text] 1,617 and the mean total direct ICU costs per septic patient were [symbol: see text] 28,582. In total costs, survivors were equally expensive as non-survivors ([symbol: see text] 28,699 vs. 28,463) although their length of study was considerably longer (21.9 vs. 13.2 days). Considering a range of patients with severe sepsis in Austria from 6,700 to 9,500 per year, total direct costs in Austria range from [symbol: see text] 192 million to [symbol: see text] 272 million. Indirect costs determined by productivity losses due to unfitness for work (temporary and permanent) and premature death amount to [symbol: see text] 484 million to [symbol: see text] 686 million in Austria per year (same incidence range). Total costs, i.e. burden of illness, combining direct costs with indirect costs, range from [symbol: see text] 676 million to [symbol: see text] 958 million.
CONCLUSION: Patients with severe sepsis have a high mortality rate, spend prolonged periods of time in the ICU, and are expensive to treat. Indirect costs of severe sepsis due to productivity losses, particularly by premature death, are considerable.

Entities:  

Mesh:

Year:  2002        PMID: 12602114

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  6 in total

Review 1.  [The cost of sepsis].

Authors:  O Moerer; H Burchardi
Journal:  Anaesthesist       Date:  2006-06       Impact factor: 1.041

Review 2.  Sepsis, severe sepsis and septic shock: changes in incidence, pathogens and outcomes.

Authors:  Greg S Martin
Journal:  Expert Rev Anti Infect Ther       Date:  2012-06       Impact factor: 5.091

Review 3.  Economic aspects of severe sepsis: a review of intensive care unit costs, cost of illness and cost effectiveness of therapy.

Authors:  Hilmar Burchardi; Heinz Schneider
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 4.  Drotrecogin alfa (activated): a pharmacoeconomic review of its use in severe sepsis.

Authors:  James E Frampton; Rachel H Foster
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

5.  Incidence and long-term outcome of sepsis on general wards and in an ICU at the General Hospital of Vienna: an observational cohort study.

Authors:  Thomas Stiermaier; Harald Herkner; Selma Tobudic; Karin Burgmann; Thomas Staudinger; Peter Schellongowski; Heinz Burgmann
Journal:  Wien Klin Wochenschr       Date:  2013-05-18       Impact factor: 1.704

6.  Antimicrobial resistance in urosepsis: outcomes from the multinational, multicenter global prevalence of infections in urology (GPIU) study 2003-2013.

Authors:  Zafer Tandoğdu; Ricardo Bartoletti; Tomasso Cai; Mete Çek; Magnus Grabe; Ekaterina Kulchavenya; Bela Köves; Vandana Menon; Kurt Naber; Tamara Perepanova; Peter Tenke; Björn Wullt; Truls Erik Bjerklund Johansen; Florian Wagenlehner
Journal:  World J Urol       Date:  2015-12-11       Impact factor: 4.226

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.